« Return to News | Drug Sponsors

Lilly expects original drugs sales to triple in India

Friday, September 16, 2011 11:15 AM

American drug maker Eli Lilly will bet on its original drugs as it aims to triple sales in India over the next five years. Unlike other foreign drug makers, it plans to stay away from acquisition of local firms or branded generics to boost its market share, according to The Economic Times.

Eli Lilly India CEO Sandeep Gupta said that instead of buying "a slew of branded generics" the company would consider selective alliances or collaborations to complement its portfolio. He said the company might consider an alliance for anti-diabetes oral hypoglycaemic agents (capsules or tablets), a segment in which it does not have a presence.

In July, the company had tied up with Mumbai-based Lupin, which will promote and distribute Eli Lilly's insulin range. Globally, the firm tied up with German drugmaker Boehringer Ingelheim earlier this year.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.